ID
ALXN

Integral Derivatives’s Alexion Pharmaceuticals ALXN Stock Holding History

Integral Derivatives’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,780
Closed -$1.89M – 1112
2017
Q4 		$1.89M Sell
15,780
-4,980
-24% -$606K 0.04% 311
2017
Q3 		$2.91M Sell
20,760
-2,540
-11% -$345K 0.05% 225
2017
Q2 		$2.83M Buy
23,300
+9,456
+68% +$1.1M 0.06% 226
2017
Q1 		$1.68M Buy
+13,844
New +$1.78M 0.03% 355
2016
Q3 		– Sell
-8,652
Closed -$1.11M – 1200
2016
Q2 		$1.01M Buy
+8,652
New +$1.23M 0.02% 416
2014
Q1 		– Sell
-1,519
Closed -$202K – 1657
2013
Q4 		$202K Buy
+1,519
New +$182K ﹤0.01% 1353

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Integral Derivatives's ALXN Position: Q1 2018 in Review

Integral Derivatives sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 15,780 shares — an estimated $1.89M sold.

Integral Derivatives first reported a position in ALXN in Q4 2013 and held it in 6 quarters. The position peaked at $2.91M in Q3 2017. 597 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Integral Derivatives reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Integral Derivatives sold 15,780 Alexion Pharmaceuticals shares in Q1 2018, an estimated $1.89M.
  • Integral Derivatives first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
  • Integral Derivatives's Alexion Pharmaceuticals position peaked at $2.91M in Q3 2017.
  • 597 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.